Impact of type 2 diabetes mellitus on in-hospital outcomes in patients with ST-elevation myocardial infarction: A nationwide study in Germany

德国一项全国性研究探讨了2型糖尿病对ST段抬高型心肌梗死患者住院结局的影响。

阅读:2

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) represents a substantial health burden especially regarding cardiovascular diseases. In this context, the presence of T2DM adversely affects both disease emergence and progression. Therefore, this study investigated the impact of T2DM on outcomes in patients hospitalized for ST-elevation myocardial infarction (STEMI). METHODS: We used the nationwide German inpatient statistics of the years 2005-2022 for statistical analysis. Hospitalizations of patients who were admitted due to STEMI in German hospitals were included in this study. The impact of T2DM on in-hospital adverse events was evaluated, whereas patients with type 1 diabetes mellitus (T1DM) were excluded. RESULTS: Overall, data on 1,590,775 hospitalizations of patients admitted due to STEMI were included; among these 379,346 (23.8%) patient-cases had T2DM. STEMI patients with T2DM were older (71.0 [62.0-79.0] vs. 66.0 [55.0-77.0] years, P < 0.001) and had an aggravated comorbidity burden. STEMI patients with T2DM were less often treated with percutaneous coronary intervention (61.2% vs. 66.7%, P < 0.001), whereas coronary-artery bypass graft was more often performed (5.0% vs. 3.9%, P < 0.001). The in-hospital case-fatality was significantly higher in T2DM patients (16.0% vs. 13.3%, P < 0.001).In multivariable analysis, T2DM was independently associated with lower usage of percutaneous intervention (OR 0.89 [95%CI 0.89-0.90], P < 0.001) and increased case-fatality (OR 1.03 [95%CI 1.01-1.04], P < 0.001). CONCLUSION: In STEMI patients, T2DM was associated with an increased case-fatality and higher complication rate in the light of an underuse of interventional revascularization.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。